In Europe, it is well established that a second medical use patent can be obtained for any second or further therapeutic use of a known drug, providing the use is novel and inventive. However, a recent judgment in the Netherlands highlights that this is a developing area of law, and that there is uncertainty.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Michiel Rijsdijk, Arnold + Siedsma, medical use patent, patent, Novartis, Paget disease,